GLP-1 Side Effects: What to Expect and How to Manage Them
The common, the rare, and the ones worth watching — plus practical strategies that reduce nausea and GI upset.
Read this first
Educational, not medical advice. If you have concerning symptoms, contact your clinician or seek urgent care. Compounded GLP-1s are prepared by licensed 503A and 503B compounding pharmacies.
The most common side effects are also the most manageable — and the rarest ones are the ones you need to know to catch. Here's the realistic map.
What are the most common GLP-1 side effects?
- Nausea — the #1 complaint; usually worst in the first few weeks and with dose increases.
- Changes in appetite, bloating, constipation or diarrhea.
- Injection-site reactions — redness or irritation where you inject.
- These tend to ease as your body adjusts, and going up doses slowly helps.
What are the rarer but serious GLP-1 risks?
- Pancreatitis — severe, persistent abdominal pain; rare but serious.
- Gallbladder problems (gallstones, cholecystitis) — increased risk in trials.
- Hypoglycemia — mainly a risk if combined with insulin or sulfonylureas.
- Kidney stress — dehydration from vomiting/diarrhea can affect kidneys.
What is the boxed warning on GLP-1s?
Wegovy and Zepbound both carry a boxed warning — the FDA's most serious label warning — for thyroid C-cell tumors. In rodent studies these drugs caused thyroid C-cell tumors; whether they do so in humans is not known.
- They are contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC).
- They are contraindicated if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- The labels also direct clinicians to monitor for new or worsening depression, suicidal thoughts, or unusual mood changes.
- Tirzepatide is not recommended in people with severe gastroparesis.
This is exactly the kind of screening a prescribing clinician is responsible for, and it is a reason the intake questions matter. Read the full prescribing information linked in the sources below.
When should you call a clinician about GLP-1 side effects?
- Severe abdominal pain, especially with vomiting
- Signs of a severe allergic reaction (swelling, trouble breathing)
- Persistent vomiting or inability to keep fluids down
- Rapid heartbeat or chest pain
How do you reduce GLP-1 nausea and GI side effects?
- Eat smaller, lower-fat meals; fat slows stomach emptying further.
- Stay hydrated, especially if you have any GI upset.
- Go up doses slowly rather than jumping.
- Don't combine with other things that upset your stomach without checking with your clinician.
Common questions about GLP-1 side effects
- What are the most common side effects of GLP-1s?
- Nausea is the number one complaint, usually worst in the first few weeks and with dose increases. Other common effects are appetite changes, bloating, constipation or diarrhea, and injection-site reactions. They tend to ease as your body adjusts.
- What is the boxed warning on GLP-1s?
- Wegovy and Zepbound carry a boxed warning, the FDA's most serious, for thyroid C-cell tumors seen in rodent studies; whether they occur in humans is unknown. They are contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.
- How do you reduce GLP-1 nausea?
- Eat smaller, lower-fat meals, stay hydrated, and increase the dose slowly rather than jumping. Avoid combining it with other things that upset your stomach without checking with your clinician first.
- When should you call a clinician about side effects?
- Seek help for severe abdominal pain, especially with vomiting; signs of a severe allergic reaction such as swelling or trouble breathing; persistent vomiting or inability to keep fluids down; or rapid heartbeat or chest pain.
Related reading
Two side effects with enough evidence behind them to need their own pages: hair loss and changes in libido and sexual function. And if you are nursing, the milk studies have a clearer answer than you might expect: semaglutide and breastfeeding.
Bottom line
Most side effects are common, expected, and manageable. A few are rare but serious and need prompt attention. This is general information — your clinician knows your history and is the right person for your specific risks.
Want this handled for you?
LunaRx — clinician-led GLP-1 care with a plan to come off
LunaRx connects you with a licensed clinician for an online evaluation. Depending on your state that is a live or a store-and-forward visit. If the clinician determines a GLP-1 is appropriate for you, a licensed pharmacy dispenses it — with a plan to come off when you’re ready. The prescribing decision is the clinician’s alone, and approval is not guaranteed.
Sources
Primary sources for the claims in this article. Trial results are reported as published; prescribing information is the authoritative reference for dosing and safety.
- 1.WEGOVY (semaglutide) injection — full prescribing information
DailyMed, U.S. National Library of Medicine · 2026
Boxed warning for thyroid C-cell tumors, MTC/MEN 2 contraindications, and the labeled adverse-reaction profile — including hair loss in 3.3% of adults on 2.4 mg (4% of women, 0.9% of men) versus 1% on placebo. The June 2026 revision warns about diabetic retinopathy complications but does not list NAION. Verified 2026-09-29.
- 2.ZEPBOUND (tirzepatide) injection — full prescribing information
DailyMed, U.S. National Library of Medicine · 2026
Boxed warning for thyroid C-cell tumors, MTC/MEN 2 contraindications, and gastroparesis guidance. Also directs patients on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting Zepbound and for 4 weeks after each dose escalation, and to discontinue when a pregnancy is recognized. Label revised 2026-08-28; verified 2026-09-30.
- 3.STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, et al. · New England Journal of Medicine · 2021
Mean weight change of −14.9% with semaglutide 2.4 mg versus −2.4% with placebo at 68 weeks.
- 4.SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, et al. · New England Journal of Medicine · 2022
Mean weight change of −20.9% on tirzepatide 15 mg at 72 weeks, in 2,539 adults without diabetes.
Get the weekly research update
New trials, FDA moves, and pricing shifts — one plain-English email a week. No spam.
Unsubscribe anytime. Read our privacy policy.
